Addison Willett, MD
Radiation Oncology · Iowa City, IANPI 1508252941
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 57 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 15.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $459 and has fallen 55.4% since, to $205 in 2025.
Across 57 payments — averaging $20.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$175
- Novocure Inc.$151
- Sanofi$72
- Merck$70
- Johnson & Johnson$68
- Eisai Inc.$55
- plus $580 from 22 others
What the payments were for
- Food & beverage$1,171100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 10 | $175 |
| Novocure Inc. | 7 | $151 |
| Sanofi | 3 | $72 |
| Merck | 3 | $70 |
| Johnson & Johnson | 4 | $68 |
| Eisai Inc. | 3 | $55 |
| Genentech USA, Inc. | 2 | $44 |
| AstraZeneca(2 entities) | 2 | $41 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $41 |
| Genmab U.S., Inc. | 2 | $41 |
| Lilly USA, LLC | 2 | $40 |
| Tersera Therapeutics LLC | 1 | $35 |
| Regeneron Healthcare Solutions, Inc. | 1 | $30 |
| Reflexion Medical, Inc. | 1 | $28 |
| Progenics Pharmaceuticals, Inc. | 1 | $26 |
| Invivyd Inc | 1 | $25 |
| Incyte Corporation | 1 | $24 |
| Daiichi Sankyo Inc. | 1 | $23 |
| Karyopharm Therapeutics Inc. | 1 | $23 |
| Pharming Healthcare, Inc. | 1 | $22 |
| Siemens Medical Solutions USA, Inc. | 1 | $22 |
| Puma Biotechnology, Inc. | 1 | $20 |
| Coherus Oncology, Inc. | 1 | $19 |
| Pharmacosmos Therapeutics Inc. | 1 | $18 |
| Bayer | 1 | $16 |
| AVEO Pharmaceuticals, Inc. | 1 | $15 |
| Exelixis Inc. | 1 | $15 |
| Amgen | 1 | $14 |
How this compares
$1,171 in reported general payments places this provider in the 80th percentile of 55 radiation oncology providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Sucralfate | 27 | $878 |
| Dexamethasone | 16 | $363 |
| Ondansetron Hcl | 20 | $207 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 12 | $176 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 16 | $166 |
| Tamsulosin Hcl | 16 | $154 |
| Pantoprazole Sodium | 13 | $78 |
Paid to pharmacies, not to this prescriber.
Other radiation oncology in Iowa City
- Kristin PlichtaIowa City$6K
- Malgorzata KozakIowa City$2K
- Mark SmithIowa City$2K
- Bryan AllenIowa City$552
- Samuel AndrewsIowa City$425
- John BuattiIowa City$419
- Kailin YangIowa City$224
- Shri Kiriti RajanIowa City$71
- Uwajachukwumma UzomahIowa City$71
- William RockeyIowa City$70
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.